Field trip news
October 7, 2020
Field Trip went public through a direct listing on the Canadian Securities Exchange after it completed a reverse takeover of oil and gas company Newton Energy Corporation.
Ronan Levy, a cofounder and the executive chairman of Field Trip, says psychedelic drugs, which are currently illegal under federal law but show promise in clinical mental health studies, will become the next blockbuster pharmaceutical products.
Field trip news
November 19, 2020
November 5, 2020
Field trip news
October 19, 2020
October 5, 2020
New research suggests that electrophysiological brain signals associated with neural plasticity could help explain the rapid, antidepressant effects of the drug ketamine. The findings, European Neuropsychopharmacology, indicate that ketamine could reverse insensitivity to prediction error in depression.
It has been a tumultuous year for the world at large, with COVID-19 necessitating sweeping changes to ways of life across nearly every geography and domain. Against this challenging backdrop, psychedelic medicine has gained a great deal of traction in 2020. Research and development—including clinical trials—has continued to gain momentum and maturity, while public opinion, regulatory bodies, and mainstream media outlets all appear to be increasingly amenable to the prospect of psychedelic medicines and therapies.
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin. Field Trip Health's Director of Research joins Benzinga to discuss future pathways & opportunities in the space.
Using talk therapy and supervised ketamine sessions to help patients battle anxiety and depression, Field Trip Health is leading the psychedelic-enhanced psychotherapy movement across the United States.
Fran Pulido As an illustrator, you may have never dreamed of seeing your work published in an app. It’s time to overcome this prejudice. In this post, illustrator Fran Pulido explains how to shine in the digital product space — a world constantly demanding visually amazing experiences and talent — and uses the Trip App as a case study for excellence.
Field Trip Health Ltd. has signed a lease to open its first psychedelics-assisted therapy clinic in The Netherlands. This will be the first Field Trip clinic to offer psilocybin treatment, leveraging the fact that mushroom truffles containing psilocybin are not criminalized in The Netherlands.
According to Independent Consultant Mort Goldman, Pharm.D., “Ketamine is relatively short-acting, with an incredibly high level of safety. That’s why it’s a favorite among doctors as a procedural anesthetic.” That’s also why ketamine seems like one of the most reasonable solutions to treating mental and emotional distress in a time when few have access to—or money for—extended psychotherapy sessions that can stretch out for years.
Field Trip Health Ltd., a global leader in the development and delivery of psychedelic therapies, and WHOOP, the human performance company, today announced a partnership whereby Field Trip will be using WHOOP Strap 3.0 to measure the biometric effects of Field Trip’s psychedelic therapies.
For many veterans of war, the battle continues even after they’ve returned home from combat. The Veterans Affairs Canada website estimates that up to 10% of their warzone veterans will suffer from PTSD or another mental health affliction, and are 14-19% more likely than the general Canadian population to commit suicide, according to their 2019 Veteran Sucide Report. While both medications and therapeutic interventions are available for this condition, they haven’t proven very effective.
Field Trip Health has shared renderings of their Jamaican facility with Psilocybin Alpha.
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.
Field Trip, the leader in the development and delivery of psychedelic therapies, today provided an update on its in-vivo and in-vitro studies on FT-104, its lead drug candidate.
CHICAGO, Oct. 22, 2020 -- Field Trip announces today the opening of their Chicago center. Located at 325 West Huron Street, Suite 603, the Chicago location is the fourth Field Trip Health center to open this year, following Toronto, New York and Los Angeles.
Earlier this week, it was announced that the U.S.-Canada border will remain closed for at least another month amid the spread of COVID-19. Luckily, one of their most useful exports at this particular moment now has a home in the U.S.: the psychedelically enhanced therapy clinic Field Trip Health just opened its first stateside location in Manhattan. The Canadian company opened its flagship clinic in Toronto back in March, calling itself “the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy.” And while the concept of psychedelically enhanced therapy isn’t itself new (you’ve probably heard about Silicon Valley’s obsession with microdosing), the ability of companies like Field Trip or Ember Health to create a sense of normalcy around the practice certainly is.
Heroic Hearts Project ("HHP"), an international nonprofit organization that connects military veterans struggling with mental trauma to psychedelic therapies, and Field Trip Health Ltd. (CSE: FTRP) ("Field Trip"), the global leader in the development and delivery of technology-enabled psychedelic therapies, today announced entry into a strategic relationship to increase access to, and awareness of, psychedelic therapies for veterans suffering from mental health disorders such as PTSD.
Field Trip Health Ltd. announces the addition of Andrew Weil, M.D., world-renowned leader and pioneer in the field of integrative medicine, to its medical advisory board. In this role, Dr. Weil will provide Field Trip with medical advice and expertise on healing-oriented approaches to healthcare, as well as guidance on extending the influence and reach of psychedelic therapies.
After feasting on two new public companies, psychedelics investors will now get a new item on the menu: Field Trip Psychedelics. Field Trip announced its RTO date after market close on Friday. It is preparing to merge with shell company, Newton Energy Corporation (CAN:NTN.H).
Field Trip Health Ltd. is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the "CSE") under the symbol FTRP tomorrow, October 6, 2020.
Field Trip Psychedelics Inc. announced Tuesday the successful synthesis of FT-104, a novel compound that is believed to have psychedelic capabilities. The conclusion comes after in-vitro and in-vivo tests confirmed that FT-104 interacts with the 5HT2A receptor, which is the main antagonist targeted by classic psychedelic drugs like LSD, psilocybin and mescaline.
The bottom line is that more and more ordinary people who may have never considered such a thing are willing to try psychedelics. And there are more and more companies emerging to help them. One is Field Trip Health, a company offering supervised in-clinic psychedelics experiences, using ketamine for psychotherapy. On their website, anyone can fill out a survey online about who they are and what they are looking for in their own mental health improvement efforts to see if they fit the criteria for psychedelics therapy.
Field Trip Health Ltd. is pleased to announce that it has completed its previously announced reverse take-over of Field Trip Psychedelics Inc. ("FTP") by way of a three-cornered amalgamation (the "Transaction"). The Company will carry on the business of FTP, which is a global leader in the development and delivery of technology-enabled psychedelic therapies. Prior to the closing of the Transaction (the "Closing"), the Company changed its name to "Field Trip Health Ltd." and consolidated the outstanding common shares of the Company (each, a "Share"), on the basis of one post-consolidation Share for every eight pre-consolidation Shares.
Field Trip Psychedelics Inc. announces the launch of its first-ever app, Trip. A first-of-its-kind app and experience, Trip allows people from anywhere in the world to access tools that support self-exploration and consciousness expansion through meditation, breathwork and more.
While I have some reservations about rolling out psychedelic therapy to the masses, I'm also not in favor of restricting access to guides, information, and support for people who might be interested in exploring this avenue of self-help or self-discovery either. In an ideal world, there would ample human guides and assistance for people who are interested in chemically-assisted therapy, but alas, there's still too many taboos (and laws) to make such access readily available and stigma-free. Is an app a sufficiently safe way to provide access instead? Jury's out, but my hunch is no — nor do I think that's what Trip is trying to achieve. And yet here we are — and at least things are moving forward, providing access to support where previously there was little to none that was publicly readily available.
Field Trip Psychedelics Inc. announces it has closed the first tranche of its Series B financing (the "Financing"), raising gross proceeds of $11.0M from a broad base of investors. The Financing was completed through a brokered private placement for which Canaccord Genuity Corp. and Stifel Nicolaus Canada Inc. jointly acted as lead agents.
Field Trip Psychedelics Inc. announces that it is expanding stateside with the opening of a first-of-its-kind clinic in New York City. The clinic, opening under the Company's Field Trip Health brand, exists to help people heal and overcome depression as well as other tough-to-beat mental health challenges through evidence-based, medically supervised psychedelic therapies.
As investors latch onto the promise of psychedelic medicines, clinics and the clinic network management business are poised to take on a major role in the psychedelics investment story.
The idea of psychedelics coming to Canada sounds very exciting however, you won’t be seeing Magic Mushroom shops popping up in your city anytime soon. What you will see are Psychedelic treatment clinics to help those with drug addiction, depression and anxiety disorders.
Field Trip Psychedelics Inc. has launched a new mental wellness program focused on serving “frontliners.” These are individuals suffering from debilitating mental health issues as a result of high-pressure occupations. Think of combat veterans, first responders, and emergency room healthcare workers.
Field Trip Psychedelics Inc., a company doing work in psychedelics and psychedelic-enhanced psychotherapy, announced the launch of Field Trip Basecamp, a long-term program focused on serving individuals suffering from debilitating mental health issues as a result of high-pressure occupations. The immediate focus of the new program will be on “frontliners,” including combat veterans, first responders, emergency room doctors, and other professionals who are regularly exposed to traumatic experiences while on the job.
Javier Hasse, Benzinga Staff Writer, reports about Field Tripping!
Field Trip Psychedelics Inc. announces the launch of the podcast Field Tripping: Epic Trips in Psychedelics with Ronan Levy. The podcast will cover psychedelics, the people that use them, industry trends and frequently asked questions. Field Tripping is available on its website (www.fieldtripping.fm) as well as on Spotify, Apple Podcasts and Google Podcasts.
Despite the fact that most non-COVID medical research and funding has come to a halt during the pandemic, there is one emerging field that is still forging ahead. The legal use of psychedelics to treat severe cases of psychological disorders, including depression, addiction and PTSD, has exploded in popularity among researchers and investors in the past two years and has garnered even more interest in recent months.
Field Trip Psychedelics Inc. ("Field Trip") is pleased to announce its sponsorship of TheraPsil (the "TheraPsil Coalition"), a British Columbia-based non-profit dedicated to facilitating legal access to psilocybin-assisted psychotherapy for terminally-ill Canadians suffering from end-of-life distress.
Field Trip offers virtual breathwork therapy sessions with a dose of ketamine.
Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic-enhanced treatments to improve mental wellness.
I am talking to Ronan Levy from "Field Trip Health" based in Canada. The company is providing clinics for evidence based legal psychedelic therapies to treat depression. But what I like about "Field Trip Health" is their attitude towards a really dated idea to call some people “sick” or “crazy”. Field Trip Health says, we treat people, not patients. “We are all sick and healthy at the same time. It’s just that some people need more support.” says Ronan.We discuss the design places for a psychedelic treatment should have. Should they look more like a spa? Or a clinic? Or do we need new designs? And do the “ well" need psychedelics to get “better"? Or should we only focus on clinically depressed people? But then again, these concepts and terms don’t work any more. Join me and Ronan talking new psychedelic solutions and why mindfullness is not enough anymore.
In the first of a series of interviews with the trailblazers of the psychedelics industry, Psilocybin Alpha spoke to Ronan Levy: Founder & Executive Chairman of Field Trip Health, Inc.
Company also announces appointment of Nathan Bryson as Chief Science Officer and Pharmaceutical Company Executives Dieter Weinand and Helen Boudreau to the Board of Directors Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, today announced the creation of Field Trip Discovery, the company’s newly formed drug development division.
The aptly named Field Trip Health clinic in Toronto is attempting to change the mental health narrative by providing clients with a ketamine-based therapy to treat depression and anxiety.
Field Trip, a company devoted to alternative psychedelic therapies, opened its first ketamine clinic in Toronto. Up next: Los Angeles and New York City. Special K isn’t just a party drug for ravers anymore.
Welcome to the first edition of Psyched, a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. MindMed Became the First Psychedelics Company to List Publicly on NEO Stock Exchange, Created New Committee
Field Trip Health Inc., a wholly owned subsidiary of Field Trip Psychedelics Inc., (“Field Trip” or the “Company“), the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, today announced the opening of its first medical centre, in Toronto, dedicated exclusively to the administration of psychedelic-enhanced psychotherapy.
Field Trip Health, a wholly owned subsidiary of Field Trip Psychedelics, a mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, debuted its first medical center in Toronto on Wednesday. The center will be dedicated exclusively to the administration of psychedelic-enhanced psychotherapy.
Field Trip Health Inc., a wholly owned subsidiary of Field Trip Psychedelics Inc., (“Field Trip” or the “Company“), the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, today announced the opening of its first medical centre, in Toronto, dedicated exclusively to the administration of psychedelic-enhanced psychotherapy. The centre seeks to enhance the lives of patients seeking mental health treatment through psychedelics and psychedelic-enhanced psychotherapy.
Field Trip Psychedelics Inc, the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, is pleased to announce the closing of its oversubscribed Series A financing round. The financing, which was completed through a private placement, raised $8.5M USD for the Company.
In 1967, Jimi Hendrix’s “Are You Experienced?” became the anthem for a generation of psychedelic initiates. Over fifty years later, at the recent Economics of Psychedelic Investing conference, the cultural touchstone was Michael Pollan’s NYT bestseller, ”How to Change Your Mind.” And as Lewis Goldberg, Principal of KCSA Strategic Communications, noted to the 200-plus attendants, it should have already been required reading for everyone in the room.
Among many esteemed guests, Ronan Levy talks the future of psychedelics and the impact potential that the space has on healthcare. Listen at the link, starting at 1:16:00.
get in touch
Are you disappointed with the results from other therapies or medications? Is something blocking progress, but you’re not sure what? Find out if psychedelic-enhanced psychotherapy is right for you.